Invitrogen, Locus enter broad kinase screening agreement

By Elaine Rigoli

Tampa, Fla., May 16 - Invitrogen Corp. announced a contract to provide Locus Pharmaceuticals, Inc. with kinase screening services through its SelectScreen platform.

Invitrogen's service will support Locus' internal kinase discovery programs, principally in the areas of cancer and inflammation, according to a news release.

Kinases are a protein family involved in many major diseases that affect humans all over the world. Over expression and mis-regulation of protein kinases are often a cause or consequence of disease.

In the past 14 months, Invitrogen said it has added an additional 123 distinct, human protein kinases onto its SelectScreen kinase screening panel.

The current collection of 193 assays addresses therapeutically relevant targets, phylogenetic diversity and key signaling pathways. The greater availability of this technology enables researchers and scientists to develop more effective therapeutic drugs to combat these diseases, the release said.

Invitrogen has headquarters in Carlsbad, Calif., and provides products and services that support academic and government research institutions and pharmaceutical and biotech companies.

Based in Blue Bell, Pa., Locus Pharmaceuticals develops novel, small molecule therapeutic drugs to address major unmet medical needs.

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.